Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 3/20 | 0.32 |
| ▸ | MMP9 | P14780 | 3/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 2/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13260893 | 1.00 | FFAR2 (0.36) | FFAR2DPP4CA12CA14MMP1 | |
| SCHEMBL14511336 | 1.00 | FFAR2 (0.36) | FFAR2DPP4CA12CA14MMP1 | |
| SCHEMBL15033256 | 0.91 | MMP1 (0.38) | FFAR2MMP1MMP9MMP14 | |
| SCHEMBL22421642 | 0.91 | MMP1 (0.38) | FFAR2MMP1MMP9MMP14 | |
| SCHEMBL29878045 | 0.91 | MMP1 (0.38) | FFAR2MMP1MMP9MMP14 | |
| SCHEMBL24337164 | 0.91 | MMP1 (0.38) | FFAR2MMP1MMP9MMP14 | |
| SCHEMBL19201193 | 0.84 | FFAR2 (0.32) | FFAR2MMP1 | |
| SCHEMBL19201191 | 0.84 | FFAR2 (0.32) | FFAR2MMP1 | |
| SCHEMBL12848639 | 0.81 | FFAR2 (0.31) | FFAR2MMP9MMP2MMP8 | |
| SCHEMBL7409829 | 0.81 | MMP1 (0.42) | MMP1MMP9ADAM17MMP3MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111479819-B | Method for preparing peptide and method for treating alkali | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023172940-A1 | METHODS FOR TREATING IMMUNE REFRACTORY LUNG CANCER | Revolution Medicines, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| WO-2023098831-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | 嘉兴优博生物技术有限公司 | 2023-06-08 | — | — | WO | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11492369-B2 | Method for producing peptide, and method for processing bases | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-11-08 | — | — | US | disclosed |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| EP-3347054-B1 | DOSING REGIMENS FOR ANTI-TF-ANTIBODY DRUG-CONJUGATES | GENMAB AS (DK) | 2021-05-05 | — | — | EP | disclosed |
| EP-3086814-B1 | DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | Bayer Pharma AG (DE) | 2020-06-24 | — | — | EP | disclosed |
| EP-2855508-B1 | CYCLOSPORIN A ANALOGS | ALLERGAN INC (US) | 2018-02-14 | — | — | EP | disclosed |
| WO-2017162663-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | SLC10A1, CD47, SELPLG | FFAR2 894/4885DPP4 1201/4885CA12 432/4885 |
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | FFAR2 4666/4885DPP4 2889/4885CA12 4023/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | FFAR2 3626/4885DPP4 3661/4885CA12 4624/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | FFAR2 4666/4885DPP4 2889/4885CA12 4023/4885 |
| US-11492369-B2 | Method for producing peptide, and method for processing bases | VIP, NPPA, PTMS | FFAR2 3340/4885DPP4 1683/4885CA12 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.